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Cancer Therapy: Preclinical
RadiotherapyCombinedwith the Immunocytokine
L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M.L. Zegers1, Nicolle H. Rekers1, Dana H.F. Quaden1,2, Natasja G. Lieuwes1,
Ala Yaromina1,Wilfred T.V. Germeraad2, Lotte Wieten3, Erik A.L. Biessen4, Louis Boon5,
Dario Neri6, Esther G.C. Troost1, Ludwig J. Dubois1, and Philippe Lambin1
Abstract
Purpose: Radiotherapy modifies the tumor microenvironment
and causes the release of tumor antigens, which can enhance the
effect of immunotherapy. L19 targets the extra domain B (ED-B) of
fibronectin, a marker for tumor neoangiogenesis, and can be used
as immunocytokine when coupled to IL2. We hypothesize that
radiotherapy in combination with L19-IL2 provides an enhanced
antitumor effect, which is dependent on ED-B expression.
Experimental Design: Mice were injected with syngeneic C51
colon carcinoma, Lewis lung carcinoma (LLC), or 4T1 mammary
carcinoma cells. Tumor growth delay, underlying immunologic
parameters, and treatment toxicity were evaluated after single-
dose local tumor irradiation and systemic administration of L19-
IL2 or equimolar controls.
Results:ED-B expression was high, intermediate, and low for
C51, LLC, and 4T1, respectively. The combination therapy
showed (i) a long-lasting synergistic effect for the C51 model
with 75% of tumors being cured, (ii) an additive effect for
the LLC model, and (iii) no effect for the 4T1 model. The
combination treatment resulted in a significantly increased
cytotoxic (CD8þ) T-cell population for both C51 and LLC.
Depletion of CD8þ T cells abolished the benefit of the com-
bination therapy.
Conclusions: These data provide the first evidence for an
increased therapeutic potential by combining radiotherapy with
L19-IL2 in ED-B–positive tumors. This new opportunity in cancer
treatmentwill be investigated in a phase I clinical study for patients
with an oligometastatic solid tumor (NCT02086721). An anima-
tion summarizing our results is available at https://www.youtube.
com/watch?v=xHbwQuCTkRc.ClinCancer Res; 21(5); 1151–60.2014
AACR.
Introduction
Radiotherapy causes cell-cycle arrest or programmed cell death
in rapidly proliferating cancer cells through the induction of DNA
damage. In addition, irradiated tumors stimulate the immune
systemby releasing tumor antigens, damage-associatedmolecular
patterns (DAMP), and through upregulation of immunomodu-
latory cell surface and secretory molecules (1–4). This promotes
the uptake of dying cells by antigen-presenting cells, and provides
crosspresentation of the tumor-derived antigens to T cells, thereby
triggering a cytotoxic T-lymphocyte response, which might cause
immunogenic cell death (ICD; refs. 1, 5, 6). In some cases, tumor
growth inhibition outside the field of radiation is observed,
termed abscopal effect, which suggests the presence of a systemic
radiation-induced antitumor immune response (7–10). Howev-
er, in general, it is unlikely that radiotherapy alone provides a
sufficient antitumor immune response. Therefore, the addition of
active immunotherapy may increase the therapeutic potential
(11–13).
Active immunotherapy is used to stimulate the immune system
acting against tumor cells. Cytotoxic T-lymphocytes and natural
killer (NK) cells play an important complementary role in the
antitumor immune response as they release specialized lytic gran-
ules, whichupon interactionwith the tumor cell create pores in the
lipid bilayer of the target cell resulting in cell death (14, 15). IL2 is a
cytokine with an essential role in the activation phase of the
immune response; it stimulates the proliferation of cytotoxic
T cells,NKcells, and regulatoryT cells, providingabalancebetween
apro- and anti-inflammatory immune response (16–18). Systemic
administration of IL2 was introduced as immunotherapy for
patients with metastatic melanoma and renal cell carcinoma,
which resulted in a higher tumor response and survival (19).
However, to reach an effective intratumoral dose of IL2 by systemic
administration, high doses ought to be administered, which often
leads to toxicity (e.g., capillary leakage syndrome, severe flu-like
symptoms, and coma; ref. 20). Currently, intratumoral injections
of IL2 are employed to reach a higher local concentration of IL2
(21, 22), which shows promising results in combination with
radiotherapy in a preclinical setting (23). However, these intratu-
moral injections are limited to accessible lesions.
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An interesting alternative is the selective delivery of IL2 to the
tumor by use of fusion proteins (16, 24). During tumor
progression, synthesis of extracellular matrix components
occurs, with in particular a modulation of vascular cell behavior
and angiogenesis (16). Fibronectin of the tumor neovascula-
ture expresses extradomain-B (ED-B), which is preserved in
mice, humans, and other mammals. ED-B expression can be
used for targeted therapies because it is overexpressed in var-
ious solid tumors [e.g., melanoma, renal cell carcinoma (RCC),
breast, colorectal, and non–small cell lung cancer], but absent
in plasma and normal tissue fibronectin (except for regenerat-
ing tissues; refs. 25–30). The small-immuno-protein (SIP) L19
was developed to specifically target the ED-B domain of fibro-
nectin. In previous studies, L19 was used for imaging and
targeted (radio)immunotherapy, proving that L19 actually
targets the tumor (31–33). Moreover, in phase I clinical studies
in patients with metastatic melanoma or RCC, administration
of the immunocytokine L19-IL2 alone, or combined with
chemotherapy (dacarbazine), was safe and showed clinical
activity according to RECIST criteria or progression-free survival
(34, 35). Dacarbazine, however, does not have the potential to
induce an antitumor immune response, stimulate the exposure
of DAMPs, or activate ICD (36), which are all favorable char-
acteristics induced by radiotherapy. Therefore, based on the
known immunogenic effects of radiotherapy and the targeted
immunostimulating potential of L19-IL2, we hypothesize that
the combination of radiotherapy with L19-IL2 will cause an




Exponentially growing C51 colon carcinoma (kindly provid-
ed by Philogen S.p.A.), Lewis lung carcinoma (LLC; kindly
provided by G. Molema, UMCG, the Netherlands), and 4T1
mammary carcinoma (ATCC CRL-2539) cell lines were cul-
tured in DMEM (Lonza) supplemented with 10% FCS in a
humidified 5% CO2 chamber at 37C. All cell lines were
directly or indirectly purchased from a cell bank that performs
cell line characterizations (short tandem repeat profiling) and
were used within 6 months after resuscitation. In addition, cells
were tested for mouse antibody production (MAP) and myco-
plasma contamination.
Chemicals/reagents/antibodies
The L19-IL2 immunocytokine and L19 (Philogen S.p.A.) were
diluted with sterile PBS (Lonza) to concentrations of 200 mg/mL
and 133 mg/mL, respectively. IL2 (Proleukin, Novartis) was dis-
solved as described by the manufacturers' guidelines and diluted
with PBS to a concentration of 67 mg/mL.
For the depletion experiments, the anti-CD8 antibody (clone
JTS169) and the isotype control (anti-Phyt IgG AFRC MAC 51),
kindly provided by Bioceros Bv, were diluted with PBS to a
concentration of 2 mg/mL.
Flow cytometric analysis was performed on cells exposed to
RBC lysis buffer (eBioscience), FC-block CD16/CD32 (BD
Biosciences), and a combination of the antibodies CD3-FITC,
CD4-APC-H7, CD8-PE-CY7, CD19-PE, CD45-V500, CD45-
Percp, CD45-PE, CD45-FITC, CD45-APC, CD45-PE-CY7,
CD3e-eFLUO450, CD4-FITC, CD8a-V500 (BD Biosciences),
and NKp46-APC (Miltenyi Biotec B.V.).
In vivo experiments
All experiments were performed in accordance with local
institutional guidelines for animal welfare and were approved
by the Animal Ethical Committee of the University of Maas-
tricht (Maastricht, the Netherlands). To induce tumors,
approximately 8-week-old immunocompetent mice were sub-
cutaneously injected with syngeneic C51 (Balb/c; 1.5  106),
LLC (C57bl/6; 0.5  106), or 4T1 (Balb/c; 1  106) tumor cells,
resuspended in basement membrane matrix (Matrigel, BD
Biosciences). Upon an average tumor volume of 200 mm3,
tumors were irradiated with a single dose (10 Gy for all
models, additional groups with 2 and 5 Gy for C51) on day
0, followed by systemic therapy (vehicle PBS/L19 13.3 mg/IL2
6.7 mg/L19-IL2 20 mg) on day 1, 3, and 5. Tumor growth and
treatment toxicity (based on body weight) were monitored
until reaching 4 times the volume at irradiation time (T4 
SV). Flow cytometry was performed on tumors, spleen, and
lymph nodes excised at day 4 of the treatment schedule.
Detailed treatment schedules are shown in Supplementary
Fig. S1.
To evaluate the causal relationship between the presence of
cytotoxic T cells and tumor growth delay, an experimental set up
was designed to deplete cytotoxic-T cells in the Balb/c mice
bearing C51 tumors. Similar to previous experiments, local irra-
diation was performed on day 0 (10 Gy) and systemic therapy
(vehicle or L19-IL2) was administrated (day 1, 2, 5). In addition,
CD8þ cells were depleted by intraperitoneal injection of 0.2 mg
(100mL) anti-CD8 antibody or the negative control anti-Phyt IgG.
The timing for the anti-CD8 injections was determined by blood
withdrawal, via puncture of the saphenous vein (i) before, (ii)
after tumor cell injection, and (iii) 2, 3, or 5 days after injection
with the blocking antibodies. The percentage CD8þ cells in the
blood was determined as described below. At the end of the
experiment, the tumorswere harvested for immunohistochemical
analysis for CD8 positivity.
Flow cytometry
The number of immune cell subpopulations present in
tumor, spleen, and lymph nodes during treatment was ana-
lyzed using FACSCanto II flow cytometry (FACS, BD Bio-
sciences). Single-cell suspensions of the tissues were obtained
using the gentleMACS dissociator and the tumor dissociation
Translational Relevance
Cancer cells have a poor immunogenicity; they are not
recognized by the immune system and therefore have the
opportunity to survive and proliferate. Radiotherapy causes
immunogenic tumor cell death, thereby releasing tumor-asso-
ciated antigens that can be detected by the immune system,
causing an antitumor immune response. Active immunother-
apy can be used to further enhance the radiotherapy-induced
antitumor immune response. The combination of local radio-
therapy to the primary tumor and systemic immunotherapy
may therefore activate and stimulate a systemic antitumor
response that provides the potential to treat patients with
metastatic disease with a curative intent.
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kit (Miltenyi Biotec B.V.) according to manufacturer's guide-
lines. Of the acquired single-cell suspension, 1.0  106 cells
were suspended in FACS buffer (PBS þ 1% FCS) for analysis.
Cells were incubated with FC-block to avoid nonspecific bind-
ing, and staining was performed using the antibodies CD3-
FITC, CD4-APC-H7, CD8-PE-CY7, CD19-PE, NKp46-APC, and
CD45-V500. The total CD45þ immune cells were selected from
the viable population of cells (filtered for debris and doublets)
for further subclassification according to the strategy described
in Supplementary Fig. S2.
To determine the efficacy of anti-CD8blocking antibody on the
presence of specific immune subpopulations, collected bloodwas
incubated with RBC lysis buffer and FC-block. Next, cells were
incubatedwithCD45-Percp,CD3e-eFLUO450,CD4-FITC,CD8a-
V500, NKp46-APC, and CD19-PE, and FACS and data analysis
was performed (Supplementary Fig. S3).
Immunofluorescence
To investigate baseline ED-B expression, 7-mm cryostat sec-
tions ofC51, LLC, and4T1 tumorswerefixed in acetone (4C) and
stained according to previous published methods (37). In brief,
sections were incubated with the purified antibodies L19-SIP or
KSF-SIP (2 mg/mL; Philochem), with rabbit anti-human-IgE
(Dako) and subsequently detected using goat anti-rabbit IgG
Alexa Fluor 488 (Life Technologies). Blood vessels and cell nuclei
were detected with rat anti-mouse CD31 (BD Biosciences) fol-
lowed by donkey anti-rat Alexa 594 (Life Technologies) andDAPI
(Life Technologies), respectively.
To quantify the ED-B expression, 3 to 12 photomicrographs
(805.5 m 805.5 m), depending on tumor size, from viable tumor
regions in the largest tumor cross-section were acquired using an
Olympus BX51WI fluorescence microscope equipped with a
Hamamatsu EM-CCD C9100 digital camera, a motorized stage
(Ludl Mac 2000), and a 10 objective. Micromanager 1.4 soft-
ware was used for automated image acquisition (38). All image
recordingswere performedwith the same settings andanalyzedby
an investigator blinded to the subject coding. Images were pro-
cessed using ImageJ software v.1.49b (NIH, Bethesda, MD). The
meanfluorescent intensity after correction for cutting and staining
artefacts per image was averaged over all images per section to
obtain ED-B intensity per tumor.
For the detection of CD8þ T cells residing in tumors, sections
were first incubatedwith anti-CD8 (clone 53.62.7, Department of
Pathology, MUMC, Maastricht, the Netherlands) and visualized
with goat anti-rabbit IgG Alexa Fluor 488 (Life Technologies).
DAPI was used as nuclear counterstain.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
Software (v5.03). For all parameters, mean  SD are reported.
ThenonparametricMann–Whitney testwas used todetermine the
statistical differences between the different treatment groups. The
log-rank (Mantel–Cox) test was used to compare the survival
curves. We used a two-way ANOVA to test the interaction (syn-
ergism) between radiotherapy and L19-IL2. AP value smaller than
0.05 was considered statistically significant.
Results
Representative sections of the ED-B expression in the C51, LLC,
and 4T1 tumors and their respective fluorescent intensity, cor-
rected for the intensity of the negative controls are shown in Fig. 1.
We observed a high, intermediate, and low ED-B expression for
the C51 (451  99), LLC (326  70), and 4T1 models (157 
143), which were significantly different from each other (all P <
0.01). On the basis of body weight measurements and animal
























High, intermediate, and low ED-B
expressing tumor models. A, ED-B
expression for C51 colon carcinoma,
Lewis lung carcinoma (LLC), and 4T1
mammary carcinoma. ED-B
expression is detected by L19(sip)
biotinylated (green), vessels by anti-
CD31 (red), and cell nuclei (DAPI
staining) in blue. Scale bar, 100 mm. B,
quantification of the ED-B expression
(intensity) is corrected for negative
control [KSF(sip) biotinylated].
 , P < 0.01;  , P < 0.001.
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Combination therapy results in complete 
remission in 75% of the tumors 
Combination therapy treatment effect is
 dependent on radiation dose 
Figure 2.
Combination therapy results in complete remission of 75% in the C51 model. A, fraction of tumors not reaching 4 times start volume (T4  SV). B, time to reach
4 times start volume for the different treatment groups. C, results of flow cytometry analysis; shown is the percentage of CD8þ and NKp46þ cells of all
CD45þ cells present in the tumor. Data represent the mean of 6 to 12 tumors.  , P < 0.05;  , P < 0.01;  , P < 0.001.
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Combination therapy results in complete remission of 75% in
the C51 model
We evaluated the time to reach four times start volume (T4 
SV) for all treatment groups in the C51 model with high ED-B
expression. Experiments were started at an average tumor
volume of 254  126 mm3. L19, IL2, or L19-IL2 monotherapy
increased the T4  SV to 6.1  0.9 (P < 0.01), 6.3  1.2 (P <
0.01), and 6.0  1.6 days (P < 0.05), respectively, as compared
with the vehicle (4.8  0.8 days) treated C51 tumor-bearing
animals, but no significant differences between these three
Lewis lung carcinoma
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Combination therapy results in an additive effect in the LLC model (intermediate ED-B) and no effect in the 4T1 model (low ED-B). A, survival curves of the
LLC and 4T1 models, showing the fraction of tumors not reaching 4 times start volume (T4  SV). B, scatter plots of the LLC and 4T1 models, showing the
time to reach 4 times start volume (T4  SV). Flow cytometric analyses of tumor leukocyte content in the LLC (C) and 4T1 (D) models, showing the percentage of
CD8þ and NKp46þ cells of all CD45þ cells in the tumor.  , P < 0.05;  , P < 0.01;  , P < 0.001.
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treatment groups were observed. Single-dose radiotherapy (10
Gy) significantly enhanced tumor growth delay when preceding
vehicle (P < 0.001), L19 (P < 0.001), or IL2 (P < 0.001)
treatment. Upon combination with L19-IL2 therapy, a highly
significant (P < 0.0001) synergistic antitumor effect was
observed with 9/12 cures (Fig. 2A and B). Reduction of the
single-dose radiations to 5 or 2 Gy showed a dose-dependent
treatment effect. For tumors treated with the combination of
ionizing radiation and L19-IL2, a cure rate of 6/12 and 1/12 was
observed for irradiation with 5 Gy (P < 0.001) and 2 Gy (P ¼
0.002), respectively, as compared with the combination with
vehicle treatment (Fig. 2A and B).
FACS analysis was performed to evaluate the underlying
immunologic parameters. The percentage of baseline cytotoxic
T cells in the tumor was 22.2%  9.2% of CD45þ cells in
vehicle-treated animals. Radiotherapy slightly enhanced the
cytotoxic T-cell subpopulation (28.1%  5.7%), without being
significant (P¼ 0.24). The percentage of cytotoxic T cells during
combination treatment was significantly higher than in vehicle
(38.6% 10.8%, P < 0.01) or L19-IL2 only (22.0% 8.8%, P¼
0.01) treated animals. There was no significant difference in the
CD45þ population in the tumor between different treatment
groups. In addition, no significant differences were observed in
NKp46þ NK cells, CD4þ T cells, or CD19þ B cells between the
treatment groups (Fig. 2C; Supplementary Table S1). Flow
cytometry of the lymph node and spleen tissue showed no
significant difference for any of the analyzed immune subpo-
pulations (CD8þ, CD4þ, CD19þ, and NK; Supplementary
Table S1).
Combination therapy results in increased growth delay in the
LLC model
Next, we investigated the possible therapeutic effect of com-
bined radiotherapy with L19-IL2 in the LLC model with inter-
mediate ED-B expression. Experiments were started at an aver-
age tumor volume of 254  148 mm3. There was no significant
difference in tumor growth delay for L19 (4.3 1.2 days) or IL2
(5.1 1.1 days) compared with vehicle (4.4 1.1 days) treated
animals. L19-IL2 monotherapy resulted in a significant tumor
growth delay (P ¼ 0.02), increasing T4  SV to 6.0  1.4 days.
Single-dose radiotherapy (10 Gy) only also showed an
increased growth delay (6.9  2.0 days; P ¼ 0.02), however,
the combination of radiotherapy with L19-IL2 resulted in the
largest growth delay (10.5  2.6). This was significantly longer
than after radiotherapy or L19-IL2 only (P < 0.01 and P < 0.001,
respectively; Fig. 3A and B). There was no significant interaction
between radiotherapy and L19-IL2 (two-way ANOVA; P ¼
0.15), the effect of the combination therapy in LLC was
additive.
The observed baseline percentage of cytotoxic CD8þ T cells in
this LLC model was significantly lower than in the C51 model
(P ¼ 0.002). The number of cytotoxic T cells as a percentage of
CD45þ cells increased significantly upon L19-IL2 treatment:
from 2.7%  1.0% (vehicle) to 7.4%  4.1% (L19-IL2, P ¼
0.04), and from 1.9%  0.8% (radiotherapy) to 4.4%  2.6%
(radiotherapyþL19-IL2, P ¼ 0.04; Fig. 3C). Radiation caused a
significant decrease in the percentage of CD19þ and CD4þ cells
in the tumor compared with vehicle treatment (Supplementary
Table S1). No differences were observed in the percentage of
NKp46þ cells in the tumor (Fig. 3C). Analysis of the lymph
nodes and spleen tissue showed no significant differences
(Supplementary Table S1).
In the low/negative ED-B–expressing 4T1 model, the addition
of L19-IL2 to radiotherapy has no effect
Next, we investigatedwhether L19-IL2 had any off-target effects
using the low ED-B–expressing 4T1 model. Experiments were
started at an average tumor volume of 152 48mm3. For the 4T1
model, no statistically significant differences were observed
between vehicle, IL2 and L19-IL2–treated animals, with an aver-
age T4  SV of 7.9  2.8, 8.7  1.6, and 9.2  2.4 days,
respectively. Single-dose radiotherapy (10 Gy) increased growth
delay significantly for all treatment groups: radiotherapyþ vehicle
(13.3 3.7 days, P¼ 0.01), radiotherapyþ IL2 (17.0 5.4 days,
P < 0.01), or radiotherapyþ L19-IL2 (17.7 4.2 days, P < 0.001);
however, no statistically significant differences (P¼ 0.47 and P¼
0.59) were observed between these irradiated groups (Fig. 3A and
B). There is no significant interaction between radiotherapy and
L19-IL2 (two-way ANOVA; P ¼ 0.20).
Radiotherapy caused a significant increase in the presence of
CD8þ T cells in the 4T1 tumor. The percentage of CD8þ T cells
increased from 6.9 1.8 (vehicle) to 18.0 12.6 (radiotherapyþ
vehicle, P ¼ 0.04) and from 6.4  2.9 (L19-IL2) to 14.2  6.4
(radiotherapy þ L19-IL2, P < 0.01). Albeit, no significant differ-
ences (P ¼ 1.0) were observed for L19-IL2–treated animals
compared with vehicle. No significant differences were observed
for the percentage ofNK cells in the tumor for any of the treatment
groups (Fig. 3D). The percentage of CD19þ cells were significantly
higher for treatment with L19-IL2 alone (4.0  1.6) compared
with vehicle (2.5  0.6, P ¼ 0.03), radiotherapy þ vehicle (2.0 
0.7, P ¼ 0.02), and radiotherapy þ L19-IL2 (1.6  1.2, P ¼ 0.04;
Supplementary Table S1). Analysis of the spleen and lymphnodes
showed no significant difference for any of the analyzed immune
cells.
Depletion of cytotoxic T cells prohibits complete remission
On the basis of our observation that radiotherapy þ L19-IL2
immunotherapy significantly increases the CD8þ T-cell subpop-
ulation, we assessed the causal relationship between the thera-
peutic effect and CD8þ T cells by depleting the CD8þ T cells in the
C51 tumor model. Tumor cell injection did not result in changed
immune subpopulations. Treatment with the CD8þ T-cell deplet-
ing (JTS169) antibody abolished CD8þ T cells in the blood 2 days
after injection (0.06%  0.06%; >99% depletion). Cytotoxic
CD8þ T cells were detectable again at day 3 (1.6%  0.7%) after
Figure 4.
Depletion of cytotoxic T cells prohibits complete remission in the C51 model. A, cartoon of treatment schedule. B, % CD8þ cells of CD45þ cells 3 days after
intraperitoneal anti-CD8, IgG, or PBS (vehicle) and an example of the flow cytometry results showing the percentage of CD3þCD8þ cells present in the blood
3 days after anti-CD8 or IgG administration. C, % of CD8þ cells present in the tumor of CD8-depleted and nondepleted mice treated with radiotherapy and
L19-IL2 analyzed by flow cytometry and an immunofluorescent CD8 staining (green), cell nuclei stained with DAPI (blue). D, fraction of tumors not reacting
4 times start volume (T4  SV) and time to reach T4  SV for the different treatment groups.  , P < 0.05;  , P < 0.01;  , P < 0.001.
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depletion and levels increased over time to 5.7%  3.0% at day
5 (Supplementary Fig. S4A). On the basis of these data, we opted
for 3 daily administrations of CD8þ depleting antibody to effect
sustained ablation of CD8þ T cells (Fig. 4A). Three days after
depletion with 0.2 mg anti-CD8 antibody, the CD8þ T-cell
population was significantly reduced in blood (P < 0.0001),
whereas the control groups receiving either isotype IgG (15.7%
 0.9%) or vehicle (18.1%  3.1%) showed similar numbers of
CD8þ cells as baseline (Fig. 4B). CD8þ T cells were also depleted
in the tumor (2.2%  2.6%, vs. 38.6%  10.8% at baseline; Fig.
4C), spleen, and lymph nodes (Supplementary Fig. S4B). Upon
depletion of cytotoxic T cells, the combination of radiotherapy
with L19-IL2 lost its therapeutic effect (T4  SV ¼ 11.25  3.0
days) and was not superior (P¼ 0.31) to radiotherapy only (T4
SV ¼ 10.0  3.0 days). However, in agreement with previous
results, the animals in the control groups (without CD8þ T-cell
depletion), still showed sustained antitumor effects (IgG: cure 5/
8, vehicle: cure 3/8) after 10 Gy irradiation and L19-IL2 (Fig. 4D).
Discussion
Radiation-induced cell death is an immunogenic process that
canbe used to initiate tumor-specific immune responses (39). The
selective delivery of IL2 to tumor vascular components is prom-
ising in cancer immunotherapy (16, 40, 41) and may be used to
enhance the therapeutic potential of radiotherapy. We hypothe-
sized that the combination of radiotherapy with the targeted
immunocytokine L19-IL2 may cause an enhanced antitumor
effect dependent on the expression of ED-B. In this study, we
assessed the therapeutic potential and underlying mechanisms of
the combination therapy in three different tumor models with
varying ED-B expression.
On the basis of growth delay experiments, the combination
therapy showed a therapeutic gain compared with the single
treatment arms, with an additive effect for the LLC model and a
long-lasting highly synergistic effect for the C51 model for
which a cure rate of 75% was observed. As expected, no effect
was observed for the 4T1 model, which has a low ED-B
expression. The results show that ED-B expression is essential
for the efficacy of combined irradiation and L19-IL2 adminis-
tration. The C51 model showed the highest ED-B expression
and the most promising results for the combination therapy
suggesting that high ED-B expression may assure better L19-IL2
tumor targeting. Like our C51 model, ED-B is overexpressed in
many solid tumors (25–27, 29, 41), which makes this combi-
nation therapy (radiotherapyþ L19-IL2) potentially interesting
for the majority of cancer types.
The highly synergistic effect observed in the C51 model upon
radiotherapy and tumor-targeted L19-IL2 treatment is in agree-
ment with previous results described by Yasuda and colleagues
(23). They observed a complete eradication of a colon carcinoma
cell line (Colon26) in Balb/c mice after the combination of
radiotherapy with intratumoral injections with IL2. For the mod-
els presented in this study, no additional benefit was observed for
the use of the single treatment with L19-IL2 in comparison with
IL2 treatment. This is in contradiction with the results from
previous studies, showing that L19-IL2 provides a stronger anti-
tumor effect compared with equimolar dosing of untargeted IL2
in an F9 teratocarcinoma or a human pancreatic carcinoma
xenograft model (16, 42). This might be explained by the use of
different mouse strains, tumor models, and treatment schedules.
However, in combination with radiotherapy, we did find a
stronger antitumor effect when using L19-IL2 compared with IL2.
This shows that, in agreement with previous results, L19-IL2 has
an increased antitumor effect.
Upon combination therapy, an increasednumber of cytotoxic T
cells was observed in the tumor of the LLC and C51 models. A
comparison between the used models shows that already at
baseline, the number of cytotoxic T cells is higher for the C51
model than for the LLC and 4T1models. Results are in agreement
with previous publications, where it was already shown that,
dependent on tumor model, the efficacy of IL2 treatment can be
based on T cells (43, 44), or a combination of NK and T cells (16).
Inmice bearing C51 colon carcinoma, L19-IL2 as single treatment
already showed an increased number of tumor-infiltrating cyto-
toxic T cells and NK cells in immunohistochemical analysis
(16). This was confirmed in the clinical setting where both cell
types were upregulated in the peripheral blood of patients as a
result of L19-IL2 treatment (34). Johnson and colleagues (45)
combined an alternative immunocytokine, KS-IL2, with radio-
frequency ablation in a murine colon adenocarcinoma (CT26).
The combination increased growth suppression, and a greater
proportion of CD4þ and CD8þ cells was observed. Further-
more, the therapeutic effect of IL2 coupled to the human
monocloncal antibodies F8 and F16 that recognize the ED-A
and ED-B domains of fibronectin and the A1 domain of
tenascin-C, respectively, was shown to be mediated by CD8þ
and NK cells in an in vivo AML model (46). Moreover, the
antibody-based targeted delivery of IL4 and IL12 to tumor
neovasculature has also been shown to eradicate tumors by
both NK and CD8þ T cells (47). In our study, we irradiated the
tumors before administration of the immunocytokine L19-IL2.
It is known that radiotherapy can promote a DC-mediated
cytotoxic T-lymphocyte (CTL) response, the so-called immu-
nogenic cell death (48). This form of cell death may be further
enhanced by the targeted delivery of IL2 to the irradiated
tumors. Our combination therapy may therefore favor the CTL
response, because NK cells are able to detect and destroy
malignant and virally infected cells directly (15). Indeed, we
have shown that depletion of the cytotoxic T cells in the C51
model inhibits the antitumor effect after combination therapy,
providing evidence that the complete remission observed in the
majority of C51 tumors, is attributed to the high number of
cytotoxic T cells present in the tumor after combination
therapy.
Evidence suggests that local radiation always elicits activation
of the immune system, even though the proportion of tumor cells
undergoing immunogenic cell deathwill vary (5, 7). Demaria and
colleagues (7) showed that a single low dose of radiotherapy (2
Gy) in combination with Flt3-Ligand (enhancing the number
of available dendritic cells) could already trigger antitumor T-
cell responses, while Schaue and colleagues (49) reported that
only doses above 7.5 Gy were immunostimulatory. To test this
in our study, the radiotherapy dose was reduced from 10 Gy to
5 Gy or 2 Gy for the C51 model. The decrease in dose of
irradiation resulted in a reduced number of tumor eradications,
showing that in this model and experimental set-up the radio-
therapy dose is an important parameter to generate cure. We
therefore suggest that a minimal radiotherapy dose is necessary
to provide sufficient immunogenic cell death to trigger the
antitumor immune response. In our experiments, we only
tested one single radiotherapy dose in combination with
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L19-IL2, showing excellent results. Therefore, we expect that the
use of a few high doses of radiotherapy (SBRT) is sufficient to
release DAMPs and initiate the antitumor immune response,
while limiting the damage to essential immunologic (CD8þ)
cells. In a previous clinical trial, Seung and colleagues (50)
combined SBRT with systemic IL2 in patients with metastatic
melanoma or RCC, which already provided a higher response
rate compared to historical data. On the basis of our results, the
use of L19-IL2, instead of systemic IL2, will increase the
potential and decrease toxicity. Therefore, the clinical set-up
combining SBRT with L19-IL2 seems very promising and will
be investigated in a clinical trial (NCT02086721).
As ED-B has an identical amino sequence inmice and humans,
the human single-chain Fv monoclonal antibody fragment L19
combinedwith IL2 can be directly used in clinical setting. In phase
I trials, L19-IL2was already safely administered inmelanoma and
renal cell carcinoma, even in combination with decarbazine,
which is not an ICD inducer like radiotherapy (34–36). On
the basis of our current results that ED-B expression is essential
to obtain a therapeutic benefit, L19-SIP imaging should be
included in a clinical trial set-up to evaluate the possibility to
select patients for L19-IL2 treatment. However, the ultimate aim
is to increase progression-free survival by the irradiation of
accessible, larger solid tumors/metastasis, initiating an antitumor
immune response that will attack the solid lesions and its
micrometastasis.
In conclusion, the combination therapy of radiotherapy with
L19-IL2 can enhance the immune response against diverse solid
tumors, providing an additive or synergistic antitumor effect in
the presence of ED-B. These findings can directly be translated to a
phase I clinical study in patients with an oligometastatic solid
tumor, because the use of L19-IL2 is proven to be safe in patients.
This promising new opportunity for cancer treatment is subject of
clinical investigation.
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